Submit interest in obtaining SARS-CoV-2 nucleocapsid protein panel for antigen test evaluation

PATH’s Diagnostics Program is actively supporting diagnostic developers and manufacturers in the COVID-19 response. Although not currently available, PATH would like to assess the interest of diagnostic developers in receiving a uniform benchmarking panel to assess COVID-19 N antigen diagnostic tests. Diagnostic developers may complete this form to indicate their interest in receiving this panel. This product is currently under development and not available at this time, but, if you provide your contact information, we will contact you upon its availability with instructions for accessing. For more information on this upcoming product, please visit its landing page: https://www.path.org/programs/diagnostics/sars-cov-2-nucleocapsid-protein-panel/ Additionally, if you are interested in accessing SARS-CoV-2 biospecimens for future research use, please complete the application at this link: https://app.smartsheet.com/b/form/b7529792364e404dbe1b6051ef066555

2. Would you be interested in receiving a uniform benchmarking panel to assess the analytical performance of your COVID-19 N antigen detection test?*

Note that this panel is not currently available, but that PATH is actively gauging demand for planning purposes.

Note one panel is required per unique diagnostic candidate/product.

Powered by Smartsheet Modern Logo On Light
Privacy Notice|Report Abuse